Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation

Liver X receptor (LXR) agonism has theoretical potential for treating NAFLD/NASH, but synthetic agonists induce hyperlipidemia in preclinical models. Desmosterol, which is converted by Δ24‐dehydrocholesterol reductase (DHCR24) into cholesterol, is a potent endogenous LXR agonist with anti‐inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Enchen, Ge, Xiaoke, Nakashima, Hiroyuki, Li, Rumei, van der Zande, Hendrik J P, Liu, Cong, Li, Zhuang, Müller, Christoph, Bracher, Franz, Mohammed, Yassene, de Boer, Jan Freark, Kuipers, Folkert, Guigas, Bruno, Glass, Christopher K, Rensen, Patrick C N, Giera, Martin, Wang, Yanan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405065/
https://www.ncbi.nlm.nih.gov/pubmed/37357756
http://dx.doi.org/10.15252/emmm.202216845

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405065/
https://www.ncbi.nlm.nih.gov/pubmed/37357756
http://dx.doi.org/10.15252/emmm.202216845

Ejemplares similares